Uterine fibroids (also called leiomyomas) are benign, noncancerous tumors that arise from smooth muscle cells within the uterus. They are among the most common gynecologic conditions affecting women of reproductive age, and their prevalence increases with age. Many individuals have fibroids without ever developing noticeable symptoms; others experience symptoms driven by fibroid location, number, size, and effects on uterine anatomy and blood flow. Understanding fibroid biology and the clinical symptom spectrum is critical because persistent abnormal uterine bleeding or pelvic pressure can substantially impair quality of life and may require timely evaluation.
Pathophysiology centers on abnormal proliferation of uterine smooth muscle cells with an interplay of hormonal and genetic factors. Although fibroids are estrogen- and progesterone-responsive, they are not malignancies and do not become cancerous in most cases. Over time, local growth patterns can distort the uterine cavity or compress adjacent structures. The distribution of symptoms is often anatomical: submucosal fibroids (within or near the endometrial cavity) are more strongly associated with heavy or prolonged menstrual bleeding and fertility-related issues; intramural fibroids (within the uterine wall) may cause bulk-related symptoms and bleeding; subserosal fibroids (on the outer uterine surface) more often produce pressure symptoms such as urinary frequency or constipation due to mass effect. Pedunculated fibroids can cause pain or torsion-like episodes when they rotate.
The symptom profile commonly includes heavy menstrual bleeding (menorrhagia), irregular bleeding (intermenstrual spotting), pelvic pressure or fullness, and menstrual-related cramping. Some patients report symptoms that appear disproportionate to visible uterine size, reflecting the functional impact of the tumor(s) on endometrium and uterine contractility. Iron-deficiency anemia can occur when chronic blood loss exceeds iron intake, leading to fatigue, weakness, and exertional dyspnea. Bulk symptoms are also typical: urinary frequency, urgency, incomplete bladder emptying, and constipation or backache can reflect compression of the bladder, ureters, or rectum.
Risk factors include increasing age, family history, early onset of menstruation, and exposure to higher lifetime estrogen levels. Protective factors and modifying influences may include pregnancy history and certain hormonal patterns; however, individual risk varies. While fibroids are generally asymptomatic, clinicians should maintain a high index of suspicion in patients with new or worsening abnormal uterine bleeding, pelvic pressure, or anemia.
Diagnosis usually begins with history and physical examination, followed by imaging. Pelvic ultrasound is typically first-line because it can distinguish fibroid morphology and location and estimate size. Transvaginal ultrasound may improve resolution, particularly for submucosal lesions. Magnetic resonance imaging (MRI) is sometimes used when ultrasound findings are limited, when surgical planning is complex, or when differentiating fibroids from other uterine pathologies. Laboratory evaluation may include a complete blood count to assess anemia and, in select cases, additional tests to exclude bleeding disorders or other etiologies.
Management depends on symptom severity, patient preferences, age, desire for future fertility, and fibroid characteristics. For mild symptoms, watchful waiting with periodic monitoring can be appropriate because some fibroids shrink after menopause. Medical therapy aims to control bleeding and pain. Options may include hormonal treatments such as progestin-based regimens and combined hormonal methods, as well as gonadotropin-releasing hormone (GnRH) agonists or antagonists for temporizing shrinkage in selected scenarios. Antifibrinolytic therapy can reduce menstrual blood loss in some patients. Pain management may incorporate nonsteroidal anti-inflammatory drugs for dysmenorrhea-like symptoms.
For persistent symptoms, procedural and surgical approaches offer definitive or durable outcomes. Myomectomy removes fibroids while preserving the uterus and may be considered for those seeking fertility. Hysterectomy provides the most complete resolution of bleeding and bulk symptoms for patients who do not desire future uterine preservation. Minimally invasive alternatives include uterine artery embolization, which reduces fibroid blood supply, and focused ultrasound (MRI-guided) in appropriate candidates. Endometrial ablation is generally reserved for specific cases and is not suitable for patients with concerns about future pregnancy.
Evidence-based counseling should address the natural history and expected response to therapy. Fibroid size and symptoms may fluctuate, and treatment selection requires shared decision-making. Patients should be advised to seek medical care when abnormal uterine bleeding becomes heavy, prolonged, or progressively worsening; when pelvic pressure interferes with daily function; or when symptoms suggest anemia (such as fatigue and dizziness).
In summary, uterine fibroids are common benign uterine smooth muscle tumors with symptom patterns strongly influenced by location and size. Although many women remain asymptomatic, a significant subset experience heavy bleeding, pelvic pressure, and anemia. Accurate diagnosis with pelvic imaging and individualized management—from watchful waiting and medical therapy to myomectomy, embolization, or hysterectomy—can improve outcomes and quality of life.
Source: WebMD
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
